Compare Oatly Group AB - ADR (OTLY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs 10X Genomics Inc — how do they compare? Oatly Group AB - ADR trades at $10.59 (market cap $330.93M), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 30.4× Oatly Group AB - ADR's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oatly Group AB - ADR for 18 Days and 10X Genomics Inc for 91 Days on average.
| OTLY | TXG | |
|---|---|---|
Market Cap | $330.93M | $10.07B |
Volume | 68,708 | 5,657,286 |
Sector | Consumer Staples | Health |
52-Week High | $15.91 | $97.74 |
52-Week Low | $8.03 | $11.48 |
Typical Hold Time | 18 Days | 91 Days |
Enterprise Value | $835.34M | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OTLY trades at $10.38 with minimal daily movement (+0.1%). The stock shows mixed signals with a bearish technical outlook but improving fundamentals. Recent Q2 2026 results showed revenue growth and margin improvement, though the company continues to post net losses. Analyst sentiment is divided with a $12.28 consensus target, representing 18% upside potential from current levels.
The investment case hinges on Oatly's ongoing turnaround efforts showing progress through revenue growth and margin expansion. Key risks include persistent negative cash flow, high debt levels, and delayed profitability. The stock offers speculative appeal for investors betting on the plant-based beverage market growth and operational improvements, but requires careful risk management.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
